Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 13/20 | 0.43 |
| ▸ | CTSD | P07339 | 8/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2283313 | 0.95 | BACE1 (0.47) | BACE1CTSDMTNR1BEGFRERBB3 | |
| Formic Acid SCHEMBL2285120 | 0.89 | BACE1 (0.43) | BACE1CTSDMTNR1BNPC1GAA | |
| Formic Acid SCHEMBL2283640 | 0.86 | BACE1 (0.57) | BACE1CTSDMTNR1BNPC1GAA | |
| SCHEMBL2283610 | 0.85 | MTNR1B (0.35) | BACE1CTSDMTNR1BNPC1MTNR1A | |
| Formic Acid SCHEMBL2283961 | 0.84 | BACE1 (0.52) | BACE1CTSDMTNR1BNPC1GAA | |
| SCHEMBL2279753 | 0.83 | BACE1 (0.47) | BACE1CTSDMTNR1BEGFRERBB3 | |
| Formic Acid SCHEMBL13685480 | 0.81 | BACE1 (0.58) | BACE1CTSD | |
| SCHEMBL2282997 | 0.80 | BACE1 (0.64) | BACE1CTSDNPC1HTR2B | |
| SCHEMBL2283004 | 0.80 | BACE1 (0.64) | BACE1CTSDNPC1HTR2B | |
| SCHEMBL13825332 | 0.80 | BACE1 (0.46) | BACE1MTNR1BGAAMTNR1AEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245019-B1 | 4, 5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-11-14 | — | — | EP | disclosed |
| US-7989449-B2 | 4,5-dihydro-oxazol-2-yl amine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20090209529-A1 | 4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209529-A1 | 4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES | BACE2, BACE1, PSEN2 | BACE1 2/4885CTSD 721/4885MTNR1B 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.